|Mr. Christopher Schelling||Founder, Pres, CEO & Director||550k||N/A||1976|
|Mr. Harry S. Palmin||COO & CFO||429.25k||N/A||1970|
|Dr. William T. Andrews M.D., FACP||Chief Medical Officer||505k||N/A||1965|
|Mr. Donald R. Joseph||Chief Legal Officer & Sec.||N/A||N/A||1954|
|Ms. Jeannie Kim||VP of Corp. Devel.||N/A||N/A||N/A|
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Acer Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.